Aatir A. Tungekar

Employment

Employment history is unavailable.

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (7)

• Understanding in-vivo refolding of antibody fragments (Fab): Biosimilar Ranibizumab a case study
  Process Biochemistry 2024 DOI: 10.1016/j.procbio.2024.09.027
  +Save
• Design of an alternate antibody fragment format that can be produced in the cytoplasm of Escherichia coli
  Scientific Reports 2023 DOI: 10.1038/s41598-023-41525-3
  +Save
• Production of neutralizing antibody fragment variants in the cytoplasm of E. coli for rapid screening: SARS-CoV-2 a case study
  Scientific Reports 2023 DOI: 10.1038/s41598-023-31369-2
  +Save
• Efficient Production of Fc Fusion Proteins in the Cytoplasm of Escherichia coli: Dissecting and Mitigating Redox Heterogeneity
  International Journal of Molecular Sciences 2022 DOI: 10.3390/ijms232314740
  +Save
• Microbial protein cell factories fight back?
  Trends in Biotechnology 2022 DOI: 10.1016/j.tibtech.2021.10.003
  +Save
• Cloning and expression of antibody fragment (Fab) I: Effect of expression construct and induction strategies on light and heavy chain gene expression
  Biochemical Engineering Journal 2021 DOI: 10.1016/j.bej.2021.108189
  +Save
• So you want to express your protein in Escherichia coli?
  Essays in Biochemistry 2021 DOI: 10.1042/ebc20200170
  +Save